The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
|
|
- Malcolm Blake
- 5 years ago
- Views:
Transcription
1 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 Review of the dossier of the proprietary drugs included on the list of reimbursable medicines for a period of 5 years as from 3 September 2005 (Official Gazette of 28 April 2006) NEXEN 100 mg, tablet B/30 (CIP code: ) NEXEN 100 mg, granules for oral solution in sachets B/30 (CIP code: ) Applicant: THERABEL LUCIEN PHARMA nimesulide ATC code: M01AX17 List I Date of Marketing Authorisation (national): 25 July 1995 Date of latest revision of Marketing Authorisation: 23 January 2008 Reason for request: Renewal of inclusion on the list of medicines reimbursable by National Health Insurance. Joint renewal of the proprietary drug: NEXEN 100 mg, tablet B/10 (CIP: ) Medical, Economic and Public Health Assessment Division 1/8
2 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient nimesulide 1.2. Indications - Treatment of acute pain - Symptomatic treatment of painful osteoarthritis - Primary dysmenorrhoea 1.3. Dosage NEXEN 100 mg tablets should be used for the shortest possible duration, as required by the clinical situation. Adults 100 mg twice a day, i.e. one tablet or one 100-mg sachet morning and evening, after meals. Elderly In elderly patients there is no need to reduce the daily dosage. Children (below 12 years) NEXEN 100 mg tablets are contraindicated in these patients. Adolescents (from 12 to 18 years) On the basis of the pharmacokinetic profile of nimesulide in adults and its pharmacodynamic properties, no dosage adjustment in these patients is necessary. Impaired renal function On the basis of the pharmacokinetic properties of nimesulide, no dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance: ml/min). However, NEXEN 100 mg tablets and granules are contraindicated in patients with severe renal impairment (creatinine clearance < 30 ml/min). Hepatic impairment NEXEN 100 mg tablets and granules are contraindicated in patients with hepatic impairment. 2/8
3 1.4. Contraindications - Known hypersensitivity to nimesulide or to any other excipients of the product; - History of hypersensitivity reactions (e.g. bronchospasm, rhinitis, urticaria) in response to acetylsalicylic acid or another non-steroidal anti-inflammatory drugs; - History of hepatotoxic reactions to nimesulide; - Active gastric or duodenal ulcer, a history of recurrent ulceration or gastrointestinal bleeding, cerebrovascular bleeding or other active bleeding or bleeding disorders; - Severe coagulation disorders; - Severe heart failure; - Severe renal impairment; - Hepatic impairment; - Children under 12 years; - The third trimester of pregnancy and breastfeeding. 2 REMINDER OF THE COMMITTEE S OPINIONS AND CONDITIONS OF INCLUSION Opinion of the Committee of 4 October 1995 These proprietary drugs offer no improvement in actual benefit over directly comparable medicines, i.e. NSAIDs, in the indication symptomatic treatment of disabling painful osteoarthritis'. Opinion of the Committee of 26 April 2000 Approval of retention of inclusion for the indication symptomatic treatment of disabling painful osteoarthritis in the indication and at the dosage in the Marketing Authorisation. Reimbursement rate: 65%. The Committee is awaiting a reassessment of the class to which this proprietary drug belongs. Opinion of the Committee of 10 January Reassessment The actual benefit conferred by this proprietary drug is minor in the indication symptomatic treatment of disabling painful osteoarthritis'. Opinion of the Committee of 2 April 2003 The Transparency Committee retains the actual benefit level previously assigned to NEXEN while awaiting the conclusions of the European arbitration procedure and reassessment of the efficacy/adverse effects ratio of nimesulide. The actual benefit conferred by NEXEN 100 mg tablets and 100 mg granules for oral solution is minor. 3/8
4 Opinion of the Committee of 16 February 2005 The actual benefit conferred by this proprietary drug in the extensions of indication (acute pain and dysmenorrhoea) is subtantial. NEXEN does not provide any improvement in actual clinical benefit compared to the alternative treatments available for acute pain and primary dysmenorrhoea. Opinion of the Committee of 30 November 2005 NEXEN has undergone a European reassessment of its risk/benefit ratio following hepatic adverse effects. This reassessment concluded that the risk/benefit ratio was favourable for all the indications in the marketing authorisation. The efficacy/adverse effects ratio of NEXEN in the treatment of osteoarthritis, acute pain and primary dysmenorrhoea was found to be similar to that of other NSAIDs (moderate). The actual clinical benefit of NEXEN is substantial. Opinion of the Committee of 20 September 2006 Approval of inclusion of NEXEN 100 mg tablets (boxes of 10 tablets). The actual benefit of this proprietary drug is substantial. This proprietary drug is an addition to the range which offers no improvement in actual benefit. 3 SIMILAR MEDICINAL PRODUCTS 3.1. ATC Classification (2010) M: Musculoskeletal system M01: Antiinflammatory and antirheumatic products M01A: Anti-inflammatory and antirheumatic products, non-steroids M01AX: Other antiinflammatory and antirheumatic products, non-steroids M01AX17: nimesulide 3.2. Medicines in the same therapeutic category All oral NSAIDs indicated for use in the treatment of acute pain and/or dysmenorrhoea and/or painful osteoarthritis Medicines with a similar therapeutic aim All analgesics. 4/8
5 4 UPDATING OF AVAILABLE DATA SINCE THE PREVIOUS OPINION 4.1. Efficacy No new clinical data has been supplied by the company Tolerance Hepatic tolerance French pharmacovigilance data Analysis of reports of hepatic adverse effects in France has shown that: - 58 cases were reported between 1998 and 2006 (one case per 3,875,000 days of treatment) - 41 cases were reported between 2007 and May 2010 (one case per 3,645,000 days of treatment). See table 1 below for the details of reports of hepatic adverse effects (severity not specified) in France. Table 1. Reports of damage to hepatic function/exposure in France Number of reports Days of treatment DT ,104, ,538, ,832, ,654, ,494, ,391, ,166, ,979, ,159, ,600, ,567, ,611, (end of May) 6 14,608,135 Total ,710,540 Summary of conclusions of European reassessments It should be remembered that nimesulide-based proprietary drugs underwent a European pharmacovigilance investigation in 2002 to assess their potential hepatotoxic risk. This investigation was carried out following the suspension of their marketing authorisation in Finland and later in Spain on the grounds of concerns regarding hepatotoxicity. Following this investigation it was decided that, despite the differing views put forward by Finland, Spain and Ireland, the efficacy/adverse effects ratio of nimesulide was still favourable provided that the SPC was amended. This amendment entailed harmonisation of 5/8
6 indications in the various European countries, a reduction of the maximum oral dose to 100 mg twice a day, the addition of a contraindication for patients with hepatic impairment and a warning regarding the risk of hepatitis, especially fulminant hepatitis, jaundice and cholestasis. These changes were taken into consideration when the Transparency Committee drew up its subsequent opinions in February and November A further European pharmacovigilance investigation was commissioned in May 2007 to reassess the potential hepatotoxicity of nimesulide following the decision by the Irish health authorities to remove nimesulide-based proprietary drugs from the market in response to reports of new cases of fulminant hepatitis. In September 2007, the conclusions of this second 1 reassessment were published by the Committee for Medicinal Products for Human Use (CHMP): assessment of all the pharmacovigilance data, clinical studies and epidemiological data has shown that the frequency of serious hepatic effects is greater for nimesulide than for other NSAIDs. However, with the exception of serious hepatic adverse effects reported in Ireland, examination of all the data submitted does not lead to any change in the tolerance profile of nimesulide as established during the first reassessment. Measures to minimise the risk were recommended, in particular amendments to the SPC 2 to emphasise that: - the decision to prescribe nimesulide must be based on an assessment of the risks; - the maximum length of treatment with nimesulide must be 15 days. Consequently, boxes containing more than 30 units must be withdrawn from the market and must not be authorised; - new contraindications must be added and the warnings must be made stronger in order to limit patient exposure, including exposure of patients with no related risk factors for hepatic effects. In addition, the retention of marketing authorisations has been made subject to the following conditions: 1. submission of PSURs (periodic safety update reports) every six months; 2. the conduct of a retrospective study, followed by a prospective study in transplant centres, to assess the relative risk of severe hepatic adverse effects leading to transplant for patients treated with nimesulide and other NSAIDs; 3. updating of the risk management plan; 4. the dispatch of a letter to inform healthcare professionals. The European Commission took the advice of the CHMP on board, imposing an additional restriction aimed at limiting the use of this medicinal product as a second-line NSAID on 16 October ,4,5. The Transparency Committee is of the opinion that serious hepatic adverse effects occurring in the short term cannot be prevented by limiting the duration of treatment to 15 days. The data available indicates that 39% of cases of hepatotoxicity have occurred within 15 days of 1 EMA. Press release European Medicines Agency recommends restricted use of nimesulide-containing medicinal products September currently being implemented in France by Afssaps 3 Commission decision dated 16 October 2009, taken pursuant to article 107 of European Parliament and Council Directive 2001/83/EC, regarding the marketing authorisation for medicinal products for human use containing the active substance nimesulide. 4 Appendix II. Scientific conclusions and reasons for retaining marketing authorisations and amendments to the summary of product characteristics and the patient information leaflet submitted by the EMEA. April Appendix V. Detailed explanation of the reasons behind the imposition of additional conditions and restrictions to the CHMP opinion. 6/8
7 the start of treatment, with 27% occurring during the first week of treatment. Furthermore, it would appear difficult in practice to comply with this restriction of treatment to 15 days in the indication "Symptomatic treatment of painful osteoarthritis". Moreover, the NSAID class contains several alternatives that are associated with a lower hepatotoxic risk. It should be remembered that several European countries have withdrawn nimesulide-based proprietary drugs from the market: Finland (2002), Spain (2002), Ireland (2007) and Belgium (2007), despite the EMA s conclusion that the benefit/risk ratio is favourable. The EMA is currently conducting a third reassessment (article 31 6 ) of nimesulide, based not only on hepatic tolerance but on the overall benefit/risk ratio. A case study review is being conducted to investigate the risk. The findings of this study will be presented to the CHMP in May Conclusion Hepatotoxicity is the main risk associated with the use of nimesulide compared to other NSAIDs. Assessment of all the pharmacovigilance data, clinical studies and epidemiological studies shows that patients taking nimesulide experience severe hepatic effects more frequently than patients taking other NSAIDs. Overall, the new tolerance data available indicating that severe hepatic effects are more common in patients taking nimesulide than in patients taking other NSAIDs, must lead to a re-examination of the efficacy/adverse effects ratio, the role in treatment strategy and the actual clinical benefit of NEXEN proprietary drugs compared to the other NSAIDs which are available. 5 DRUG USAGE DATA IMS-EPPM data (November 2009) shows that 1,763,000 prescriptions for these proprietary drugs have been issued. The average dosage was 1.9 units a day, and the average length of treatment prescribed was 15.7 days. 6 This article states that, in particular cases of Community interest, the CHMP can be asked to consider a question before a decision relating to the amendment, suspension or withdrawal of a marketing authorisation is taken. 7/8
8 6 TRANSPARENCY COMMITTEE CONCLUSIONS 6.1. Re-evaluation of actual benefit Osteoarthritis is a chronic disabling disease. Acute pain and dysmenorrhoea are not normally serious conditions, but can reduce quality of life. NEXEN proprietary drugs are intended as symptomatic therapy. The tolerance data available has indicated that patients taking nimesulide experience severe hepatic adverse effects more frequently than patients taking other NSAIDs. Consequently, the efficacy/adverse effects ratio of nimesulide-based proprietary drugs is inferior to that of other NSAIDs which are available. As a result, these proprietary drugs have no role in treatment strategy. There are numerous alternative treatments. In the light of this, the Transparency Committee considers that the actual benefit of these propriety drugs, in comparison with other treatments that are already available, is not sufficient to allow it to be refundable by National Health Insurance Transparency Committee recommendations The Transparency Committee does not recommend maintaining inclusion on the list of medicines refundable by National Health Insurance or on the list of medicines approved for hospital use and various public services in the indications and at the dosages in the Marketing Authorisation. The Transparency Committee recommends removal from the list of medicines refundable by National Health Insurance and from the list of medicines approved for hospital use and various public services in the indications and at the dosages in the Marketing Authorisation. 8/8
Opinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 IMUREL 50 mg, film-coated tablet (B/100) (CIP: 34009 364 149 0 7) IMUREL 25 mg, film-coated tablet (B/50)
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 ACADIONE 250 mg, sugar-coated tablet Bottle of 120 (CIP: 34009 329 390 7 7) Applicant: SANOFI-AVENTIS
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationTransparency Committee Opinion 8 January 2014
The legally binding text is the original French version Transparency Committee Opinion 8 January 2014 RHINOTROPHYL, nasal spray, solution Vial of 20 ml (CIP: 34009 309 102 6 9) Applicant: JOLLY-JATEL INN
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 Examination of the dossier of the proprietary medicinal product included on the list for a limited
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 TROLOVOL 300 mg, film-coated tablet B/30 (CIP: 34009 320 316 9 6) Applicant: IMAXO INN ATC Code (2012)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 4 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 January 2012 Examination of the dossier for a medicinal product included for a 5-year period starting on 7 January
More informationOpinion 20 March 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 March 2013 KETUM 2.5%, gel B/1 tube of 60 g (CIP: 333 549-7) B/1 tube/dispenser of 60 g (CIP: 344 444-7) B/1 tube/dispenser
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 DIDRONEL 200 mg, tablets B/60 (CIP code: 345 098-5) DIDRONEL 400 mg, tablets B/14 (CIP code: 333
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 ARCOXIA 30 mg, film-coated tablet B/28 (CIP code: 387 980-8) B/98 (CIP code: 573 530-9) ARCOXIA 60
More informationTRANSPARENCY COMMITTEE OPINION. 15 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 TANDEMACT 30 mg/20 mg tablets Box of 30 (CIP: 386 566-3) Box of 90 (CIP: 386 568-6) TANDEMACT 30 mg/4
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 17 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 17 October 2012 Examination of the dossier for proprietary medicinal products included for a 5-year period starting
More informationAnnex I. List of medicinal products and presentations
Annex I List of medicinal products and presentations Member State EU/EEA Applicant (Invented) Name INN + Strength Pharmaceutical form 4 Route of administration 5 Austria Ibucomb 500mg/150mg film Belgium
More informationSummary of product characteristics (SmPC)
Summary of product characteristics (SmPC) What is it and what does it contain? An agency of the European Union Table of contents 1.What is the summary of product characteristics (SmPC)? 2.Where SmPC information
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
The European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 December 2005 EMEA/357981/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON PROCEDURES
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Examination of the dossier of medicinal products included on the reimbursement list for a period of 5
More informationTRANSPARENCY COMMITTEE OPINION. 26 November 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 November 2008 CHONDROSULF 400 mg, capsule Box containing 84 capsules (CIP: 335 917-3) CHONDROSULF 400 mg, granules
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 January 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 January 2013 The opinion adopted by the Transparency Committee on 4 July 2012 was given a hearing on 5 December
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 April 2011 Review of the dossier for a proprietary medicinal product listed for a limited duration in accordance
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 IKARAN LP 5 mg, tablets B/30 (CIP: 339 287-4) IKARAN Ge 2 mg/ml, oral solution in drops Vial of 50 ml
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 ANAPEN 0.50 mg/0.3 ml, solution for injection in pre-filled syringe 1 pre-filled syringe (glass), box of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 OKIMUS, coated tablets B/2 blister strips of 20 tablets (CIP code: 363 666-1) Applicant: BIOCODEX Quinine
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 18 Scientific conclusions Overall
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 June 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 June 2010 COLOKIT, tablets B/32 (CIP: 347 188-1) Applicant: MAYOLY SPINDLER Monosodium phosphate monohydrate Anhydrous
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 December 2007 METHADONE AP-HP 1mg, gelatin-coated capsule Box of 7 (CIP: 379 146-2) METHADONE AP-HP 5mg, gelatin-coated
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 TAMIK Ge 3 mg, soft capsule B/60 (CIP code: 322 714-1) Applicant: IPRAD dihydroergotamine mesylate ATC
More information(Invented) name Strength. Leflunomide Apotex 10 mg Tablet Oral use. Leflunomide Apotex 20 mg Tablet Oral use
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states 1 Member State EU/EEA Marketing authorisation
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 SMECTA, powder for oral solution in sachets 30 sachets of 3.76 g (CIP: 34009 319 230-7 7) 60 sachets
More informationOpinion 8 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 8 January 2014 WYSTAMM 1 mg/ml, oral solution 120 ml vial with syringe for oral administration (CIP: 34009 222 560
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 January 2007 DICLOFENAC SODIUM MIKA PHARMA 4%, skin spray solution 7.5 g Vial (CIP: 362 261-8) 12.5 g Vial (CIP:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 3 mg/ml oral solution B/1 160 ml (CIP code: 491 474-8) Applicant: NOVARTIS PHARMA SAS valsartan
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Diclofenac Orifarm, 11.6 mg/g gel. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 gram Diclofenac Orifarm gel contains 11.6 mg (1.16%)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 SEGLOR 5 mg, hard capsule B/30 (CIP code: 321 899-8) SEGLOR LYOC 5 mg, oral lyophilisate B/30 (CIP code:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T, oral lyophilisate B/30 (CIP: 378 011-6) B/100 (CIP code: 378 012-2) B/90 (CIP code:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 June 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 June 2011 SPASFON, film-coated tablets B/30 (CIP code: 309 860-8) SPASFON, suppositories B/10 (CIP code: 309 861-4)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 FLEXEA 625 mg, tablet Box of 60 tablets (CIP: 34009 380 534 2 5) Box of 180 tablets (CIP: 34009 380
More informationDecentralised Procedure. Public Assessment Report. ALGOTRA 37.5 mg/325 mg überzogene Tabletten Tramadol/Paracetamol DE/H/3688/001/DC
Decentralised Procedure Public Assessment Report ALGOTRA 37.5 mg/325 mg überzogene Tabletten Tramadol/Paracetamol DE/H/3688/001/DC Applicant: Laboratoires SMB S.A. Reference Member State DE TABLE OF CONTENTS
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 September 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 September 2011 GAVISCON PEPPERMINT, chewable tablet B/20 (CIP code: 367 909-6) GAVISCON, oral suspension 250 ml
More informationAnnex II. Scientific conclusions
Annex II Scientific conclusions 7 Scientific conclusions Overall summary of the scientific evaluation of methadone products for oral use containing povidone Methadone is a synthetic opioid. Methadone is
More informationTRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 TEMERIT DUO 5 mg/12.5 mg, film-coated tablets Pack of 30 (CIP: 393 976-9) Pack of 90 (CIP: 393 977-5)
More informationTRANSPARENCY COMMITTEE OPINION. 13 December 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 December 2006 HELIKIT 75 mg, powder for oral solution CIP : 343 132-1 Applicant : MAYOLY SPINDLER 13 Curea anhydrous
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Omnilax 10 g powder for oral solution, sachet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 10 g of macrogol 4000.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 April 2011 METEOXANE, capsules B/60 (CIP code: 306 693-3) Applicant: IPRAD Simethicone Hydrated phloroglucinol ATC
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationEuropean Medicines Agency decision
EMA/87776/2014 European Medicines Agency decision P/0043/2014 of 26 February 2014 on the acceptance of a modification of an agreed paediatric investigation plan for rupadatine fumarate (Rupafin and associated
More informationSummary Public Assessment Report. Generics. Etoricoxib Aurobindo. 30 mg, 60 mg, 90 mg, 120 mg Film-coated tablet (Etoricoxib) PT/H/1603/ /DC
Summary Public Assessment Report Generics 30 mg, 60 mg, 90 mg, 120 mg Film-coated tablet (Etoricoxib) Date: 08-03-2017 Summary PAR Generics 1/10 Summary Public Assessment Report Generics 30 mg, 60 mg,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 July 2006 Doc. Ref. EMEA/186279/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON LEGAL STATUS FOR THE SUPPLY TO THE PATIENT OF CENTRALLY AUTHORISED
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationDecentralised Procedure. Public Assessment Report. Metamizol Midas / Metamizol STADA / Mimetanal 500 mg Tabletten. Metamizole sodium monohydrate
Decentralised Procedure Public Assessment Report Metamizol Midas / Metamizol STADA / Mimetanal 500 mg Tabletten Metamizole sodium monohydrate DE/H/4091-4093/001/DC Applicant: Midas Pharma GmbH, Germany
More information(Legislative acts) REGULATIONS
31.12.2010 Official Journal of the European Union L 348/1 I (Legislative acts) REGULATIONS REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 MENINGITEC suspension for injection in prefilled syringes meningococcal group C oligosaccharide conjugate
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 EXFORGE HCT 5 mg/160 mg/12.5 mg, film-coated tablets B/30 (CIP code: 397 327-5) B/56 (CIP code: 397
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 RECTOGESIC 4 mg/g, rectal ointment B/1 (CIP 376 537-0) Applicant : PROSTRAKAN PHARMA SAS Glyceryl trinitrate
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 17 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 17 November 2010 MEPACT 4 mg, powder for suspension for infusion B/1 (CIP code: 398331 6) Applicant : IDM PHARMA S.A.S
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 18/08/2017 SmPC and PL. 24/05/2017 SmPC, Annex II, Labelling
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationEuropean Medicines Agency decision
EMA/124630/2012 European Medicines Agency decision P/0055/2012 of 26 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for rabeprazole (sodium) (Pariet and associated
More informationPronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for
More informationPublic Assessment Report. Scientific discussion. Pentasa Compact 4 g, prolonged-release granules. (mesalazine) NL License RVG:
Public Assessment Report Scientific discussion Pentasa Compact 4 g, prolonged-release granules (mesalazine) NL License RVG: 114015 Date: 30 March 2015 This module reflects the scientific discussion for
More informationTRANSPARENCY COMMITTEE OPINION. 10 March 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 FIBROGAMMIN 62.5 U/ml, powder and solvent for injection or infusion B/1 Powder in vial + 4 ml of solvent
More informationHealth Products Regulatory Authority IPAR. Public Assessment Report. Scientific discussion
IPAR Public Assessment Report Scientific discussion Magnaspartate 243mg Powder for Oral Solution MAGNESIUM ASPARTATE DIHYDRATE IE/H/436/001/DC Date: 3 rd November 2014 This module reflects the scientific
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 April 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 April 2008 TAMIFLU 12 mg/ml, powder for oral suspension One bottle of 30 g (CIP: 359 963-5) TAMIFLU 75 mg, hard
More informationDecentralised Procedure. Public Assessment Report. Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten. Lorazepam DE/H/4558/ /DC
Decentralised Procedure Public Assessment Report Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten Lorazepam DE/H/4558/001-002/DC Applicant: neuraxpharm Arzneimittel GmbH, Germany Reference Member State
More informationPublic Assessment Report Scientific discussion. Aspirin (acetylsalicylic acid) Asp no:
Public Assessment Report Scientific discussion Aspirin (acetylsalicylic acid) Asp no: 2015-0454 This module reflects the scientific discussion for the approval of Aspirin. The procedure was finalised on
More informationResearch Topics. ENCePP Plenary Survey (April 2011) An agency of the European Union
Research Topics ENCePP Plenary Survey (April 2011) An agency of the European Union Q: Can you suggest any research topics that you would like to see included in public funding programmes? More than 40
More informationHealth Products Regulatory Authority IPAR. Public Assessment Report for a Medicinal Product for Human Use. Scientific discussion
IPAR Public Assessment Report for a Medicinal Product for Human Use Scientific discussion Advil Cold & Flu Coated Tablets Ibuprofen 200mg Pseudoephedrine Hydrochloride 30mg PA0822/164/001 The Public Assessment
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Suvaxyn PCV suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml contains:
More informationWyss Zürich Regulatory Affairs Seminar
Wyss Zürich Regulatory Affairs Seminar Hospital Exemption & Compassionate Use EU Framework Catherine Longeval Koen T Syen Zürich, 5 July 2017 1 Table of contents Introduction Hospital Exemption Implementation
More informationVOLUME 6A Procedures for marketing authorisation
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 27.09.2007 ENTR/F2/KK D(2007) Revision September 2007 NOTICE TO APPLICANTS VETERINARY MEDICINAL
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 April 2008 YONDELIS 0.25 mg, vial containing powder for concentrate for solution for infusion Box containing 1 vial
More informationPublic Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium
Public Assessment Report Scientific discussion Rabeprazolnatrium Torrent Pharma 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium DK/H/1819/001-002/DC This module reflects the scientific discussion
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 October 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 October 2011 PEDIAVEN AP-HP G15, solution for infusion 1000 ml of solution in two chamber bag, B/4 (CIP code: 419
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 February 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 February 2011 FONZYLANE 150 mg, film-coated tablet B/20 (CIP code: 346 595-2) Applicant: CEPHALON FRANCE Buflomedil
More informationLaura Beatriz Herrero Montarelo, Maria Dolores Gómez Vázquez and Victorio José Teruel Muñoz
Collaboration Laura Beatriz Herrero Montarelo, Maria Dolores Gómez Vázquez and Victorio José Teruel Muñoz Nutritional Risk Management Area of the Subdirectorate-General for Food Safety Promotion Spanish
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklo-f 500 mg film coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains tranexamic acid 500 mg For the full
More informationSummary of the Risk Management Plan
Summary of the Risk Management Plan Summary of Risk Management Plan for Esmya (Ulipristal Acetate) This is a summary of the risk management plan (RMP) for Esmya. The RMP details important risks of Esmya,
More informationMESULID 100 REVISED PRODUCT INFORMATION
MESULID 100 REVISED PRODUCT INFORMATION COMPOSITION Each caplet of MESULID 100 contains: Nimesulide 100 mg. Inactive Ingredients Lactose, microcrystalline cellulose, sodium starch glycolate, hydrogenated
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationTRANSPARENCY COMMITTEE OPINION. 1 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 1 April 2009 CYCLADOL 20 mg, scored tablet Box of 14 (CIP: 336 095-7) CYCLADOL 20 mg, effervescent tablet Box of 14
More information(Acts whose publication is obligatory) REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004
30.4.2004 Official Journal of the European Union L 136/1 I (Acts whose publication is obligatory) REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 laying down
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 24 Scientific conclusions Overall
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 08/03/2018 n/a
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationDECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) Federal Office of Consumer Protection and Food Safety Mauerstraße 39-42 10117 Berlin (Germany) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE
More informationMedicinal Product no longer authorised
MAJOR CHANGES 1 Procedural steps taken and scientific information after the authorisation Trudexa No Scope Opinion issued on Commission Decision II/0037 Update of of Characteristics To update section 5.1
More informationPart VI: Summary of the risk management plan by product
Part VI: Summary of the risk management plan by product VI.1 Elements for summary tables in the EPAR VI.1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Hepatotoxic
More informationDecentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack
Decentralised Procedure Public Assessment Report Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack Memantin-ratiopharm Starterpackung 5 mg /10 mg /15 mg /20 mg Filmtabletten ;10 mg/20 mg Filmtabletten
More informationHolders of European Union marketing authorizations
PRAC Experience The legal framework The Pharmacovigilance legislation (Regulation No 1235/2010 and Directive 2010/84/EU) was adopted by the European Parliament and European Council in December 2010. The
More informationOpinion 8 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 8 January 2014 LOJUXTA 5 mg, hard capsule B/28 (CIP: 34009 276 259 9 2) LOJUXTA 10 mg, hard capsule B/28 (CIP: 34009
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationCHAPTER 3. September 2007
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/SM D(2007) Revision September 2007 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing
More information